Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

[1]  M. Baccarani,et al.  Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. , 2004, Clinical chemistry.

[2]  M. Andreeff,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[3]  G. Ehninger,et al.  CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid , 2004, Annals of Hematology.

[4]  A. Anagnostopoulos,et al.  Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases , 2004, Leukemia.

[5]  Q. Waisfisz,et al.  Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene , 2004, Leukemia.

[6]  B. Druker,et al.  Lessons learned from the development of imatinib. , 2004, Leukemia research.

[7]  H. Kantarjian,et al.  High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.

[8]  B. Druker,et al.  Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography , 2004, Leukemia.

[9]  M. Polymeropoulos,et al.  Correlation of Major Cytogenetic Response with a Pharmacogenetic Marker in Chronic Myeloid Leukemia Patients Treated with Imatinib (STI571) , 2004, Clinical Cancer Research.

[10]  A. Reiter,et al.  Imatinib and beyond—the new CML study IV , 2004, Annals of Hematology.

[11]  G. Ehninger,et al.  P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate , 2004, Leukemia.

[12]  D. Scheinberg,et al.  A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. , 2004, Blood.

[13]  H. Kantarjian,et al.  Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls , 2004, Clinical Cancer Research.

[14]  G. Daley,et al.  Mechanisms and implications of imatinib resistance mutations in BCR-ABL , 2004, Current opinion in hematology.

[15]  M. Tulliez,et al.  Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. , 2003, Blood.

[16]  P. Paschka,et al.  Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C , 2003, Leukemia.

[17]  Martin C. Müller,et al.  ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. , 2003, Leukemia research.

[18]  R. Larson,et al.  Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. , 2003, Leukemia research.

[19]  J. Larghero,et al.  Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. , 2003, Biochemical pharmacology.

[20]  H. Kantarjian,et al.  Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia in chronic phase , 2003, Cancer.

[21]  F. Baron,et al.  Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. , 2003, Cancer genetics and cytogenetics.

[22]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[23]  B. Löwenberg.  Minimal residual disease in chronic myeloid leukemia. , 2003, The New England journal of medicine.

[24]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[25]  J. Griffin,et al.  Resistance to imatinib (Glivec): update on clinical mechanisms. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  F. Lauria,et al.  Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI) , 2003, European journal of haematology.

[27]  B. Druker,et al.  Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib , 2003, Pharmacological Reviews.

[28]  M. Mauro,et al.  Transplantation for chronic myelogenous leukemia: yes, no, maybe so…an Oregon perspective , 2003, Bone Marrow Transplantation.

[29]  P. Paschka,et al.  Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission , 2003, Leukemia.

[30]  D. Hedley,et al.  Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell‐based measure of Bcr/Abl kinase activity , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[31]  D. Huhn,et al.  Imatinib in Philadelphia chromosome‐positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome , 2003, American journal of hematology.

[32]  V. Najfeld,et al.  The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. , 2003, Experimental hematology.

[33]  W. Hofmann,et al.  Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. , 2003, Blood.

[34]  Susan Branford,et al.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.

[35]  M. Slovak,et al.  Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. , 2003, Blood.

[36]  C. Sandoval,et al.  Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance. , 2003, Journal of pediatric hematology/oncology.

[37]  B. Druker,et al.  Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.

[38]  J. Gabert,et al.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.

[39]  H. Kantarjian,et al.  Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. , 2003, Blood.

[40]  C. Peschel,et al.  Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back , 2003, Leukemia.

[41]  B. Dörken,et al.  Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique , 2003, Annals of Hematology.

[42]  A. Hochhaus.  Cytogenetic and molecular mechanisms of resistance to imatinib. , 2003, Seminars in hematology.

[43]  C. Herold,et al.  Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment , 2003, Leukemia.

[44]  J. Melo,et al.  Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies. , 2003, Seminars in hematology.

[45]  J. Abgrall,et al.  Double minutes containing amplified bcr‐abl fusion gene in a case of chronic myeloid leukemia treated by imatinib , 2003, European journal of haematology.

[46]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[47]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[48]  K. Krohn,et al.  Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. , 2003, Blood.

[49]  R. Braziel,et al.  Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate , 2003, Leukemia.

[50]  A. Hagemeijer,et al.  Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib , 2003, Leukemia.

[51]  Rocco Piazza,et al.  Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. , 2003, The Lancet. Oncology.

[52]  W. Hiddemann,et al.  Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate , 2003, Leukemia.

[53]  M. Zucchetti,et al.  α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients , 2003 .

[54]  H. Kantarjian,et al.  Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. , 2003, Blood.

[55]  A. Hochhaus,et al.  Resistenz auf tumorspezifische Therapie mit Imatinib durch klonale Selektion mutierter Zellen , 2002 .

[56]  Gabriela Chiosis,et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. , 2002, Blood.

[57]  S. O’Brien,et al.  Position paper on imatinib mesylate in chronic myeloid leukaemia * , 2002, British journal of haematology.

[58]  B. Druker,et al.  The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. , 2002, Blood.

[59]  P. Paschka,et al.  Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α , 2002, Leukemia.

[60]  B. Druker,et al.  Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571* , 2002, The Journal of Biological Chemistry.

[61]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[62]  G. Daley,et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. , 2002, Blood.

[63]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[64]  C. Sawyers,et al.  Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[65]  L. Kjeldsen,et al.  Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8 , 2002, Leukemia.

[66]  B. Druker,et al.  In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. , 2002, Experimental hematology.

[67]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[68]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[69]  M. Zucchetti,et al.  Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. , 2002, Blood cells, molecules & diseases.

[70]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[71]  S. de Vos,et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.

[72]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[73]  C. Peschel,et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.

[74]  S. O'brien,et al.  Spontaneous Reversion from Blast to Chronic Phase after Withdrawal of Imatinib Mesylate in a Patient with Chronic Myelogenous Leukemia , 2002, Leukemia & lymphoma.

[75]  V. Najfeld,et al.  Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571 , 2001, Leukemia.

[76]  B. Druker,et al.  Roots of Clinical Resistance to STI-571 Cancer Therapy , 2001, Science.

[77]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[78]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[79]  J. Griffin,et al.  ARG tyrosine kinase activity is inhibited by STI571. , 2001, Blood.

[80]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[81]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[82]  H. Mano,et al.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. , 2001, Blood.

[83]  J. Topaly,et al.  Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells , 2001, Leukemia.

[84]  W. R. Bishop,et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. , 2001, Blood.

[85]  K. Kolibaba,et al.  Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. , 2000, Blood.

[86]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[87]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[88]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[89]  N. Cross,et al.  Detection and quantification of residual disease in chronic myelogenous leukemia , 2000, Leukemia.

[90]  N. Heisterkamp,et al.  Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. , 1994, Blood.

[91]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.

[92]  D. Niederwieser,et al.  Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy , 2004 .

[93]  H. Kantarjian,et al.  The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase , 2004, Cancer.

[94]  J. Goldman,et al.  Chronic myeloid leukemia-still a few questions. , 2004, Experimental hematology.

[95]  B. Druker,et al.  High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. , 2004, The hematology journal : the official journal of the European Haematology Association.

[96]  D. Marin,et al.  Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. , 2003, Haematologica.

[97]  B. Druker,et al.  No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). , 2003, The hematology journal : the official journal of the European Haematology Association.

[98]  M. Zucchetti,et al.  Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  M. Baccarani,et al.  Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. , 2003, Haematologica.

[100]  P. Browett,et al.  Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase , 2003, Leukemia.

[101]  D. Marin,et al.  Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. , 2003, Haematologica.

[102]  J. Sierra,et al.  Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. , 2003, Haematologica.

[103]  M. Schwarz,et al.  Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. , 2002, Blood cells, molecules & diseases.

[104]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[105]  B. Druker,et al.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.

[106]  P. Rosée,et al.  Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective , 2002, Leukemia.

[107]  A. Hochhaus,et al.  [Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]. , 2002, Deutsche medizinische Wochenschrift.

[108]  H. Kantarjian,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-� , 2022 .